Moberg Pharma (Stockholm: MOB.ST) is a Swedish pharmaceutical company that commercializes over-the-counter (OTC) products in more than 40 countries. The Company specializes in products for the treatment of skin diseases, and has successful OTC products that address discolored or damaged nails typically caused by nail fungus. Moberg is using its domain expertise to develop a prescription product, MOB-015, using the same nail-penetrating platform technology as the OTC product. MOB-015 topically delivers the anti-fungal terbinafine as a treatment for onychomycosis and has been successfully tested in a Phase II trial. Moberg is actively seeking a partner for a potential Phase III program. Phase II data are expected from a second prescription program for oral pain in the second quarter of 2015.